GlobeNewsWire
05 Jun 2026, 23:35 UTC · 3h ago
Story key points
4 claims · impact-rated
Afrezza (inhaled insulin) demonstrated a substantially faster pharmacodynamic effect than insulin lispro, with over 50% of its effect occurring within 60 minutes compared to 10% for lispro. — Superiority in onset and offset speed reduces the risk of insulin stacking and improves dosing flexibility, providing a strong competitive advantage over standard rapid-acting analogs.
+0.60Inhaled insulin showed comparable efficacy and fewer hypoglycemic events compared to rapid-acting analogs in an interim analysis of patients with gestational diabetes. — Successful expansion into the gestational diabetes market represents a new patient population and potential revenue growth driver.
+0.40Pediatric participants achieving HbA1c <8% reported statistically greater treatment satisfaction with Afrezza compared to rapid-acting analogs. — Higher patient satisfaction in the recently approved pediatric demographic (ages 6+) is likely to drive higher adoption and retention rates.
+0.30Continue reading
6 related stories
Top 3 movers · tap to explore
A subgroup analysis in youth with HbA1c ≤9.5% confirmed that inhaled insulin is non-inferior to rapid-acting analogs in mean HbA1c reduction and Time in Range (TIR). — Confirms the drug's efficacy in a key pediatric subgroup, supporting its clinical viability but providing no new 'breakthrough' data over existing approvals.
+0.20Ticker attribution
Model heads
The company announced positive clinical and real-world data for its products Afrezza and FUROSCIX, demonstrating efficacy and safety in pediatric and gestational diabetes.
No ticker relationship head found.
Early access
News Impact Screener scores every headline against the stocks it moves — before the chart reacts. Join the early-access list and get alerted the moment a story hits your tickers.
Impact vectors
5 dimensions · 9 clusters
Market reaction
10 bid · 0 offered
No stock impact ranking available yet.
GlobeNewsWire
3h ago
